PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
MetaLabs has shifted its center of gravity from fashion licensing to hospital management consulting and pharmaceutical distribution, driving rapid revenue growth, but net losses attributable to owners have yet to be resolved.
2025 consolidated revenue rose 112% year over year to KRW 81.3 billion, but the company posted an operating loss of KRW 7.2 billion.
Operating profit turned positive in both the first and second quarters of 2026, but net income attributable to owners remained in the red.
A KRW 6 billion third-party share issuance involving parties related to the controlling shareholder is expanding control over subsidiary Metacare.
The debt ratio climbed from 52.4% in 2023 to 76.2% in 2025, and operating cash flow has been negative for three consecutive years.
Subsidiary Metacare has seen reported declines in cash holdings and rising borrowings since its acquisition, raising financial burden concerns.
MetaLabs operates a business structure broadly split into a fashion segment and healthcare-related segments covering management consulting and pharmaceutical or medical device distribution.
The fashion segment sells casual apparel and accessories online and offline under five licensed brands, with overseas wholesale and retail conducted through affiliates in Shanghai, New York, and Milan.
The management consulting segment, run mainly through subsidiary Momolabs, provides MSO (management service organization) services to hair transplant and hair loss clinics, covering marketing, HR, and facility management excluding actual medical procedures.
The healthcare segment operates through subsidiary Meta S&C (formerly Metacare) and KOSPI-listed subsidiary Metacare (formerly S-Medi), distributing pharmaceuticals and medical devices while also developing non-reimbursed CRM solutions for hospitals.
The controlling shareholder is Weber Labs, and related parties such as Meta Pharm have repeatedly participated in capital raises across the affiliate structure.
In 2024, MetaLabs acquired a 29.99% controlling stake in S-Medi, a subsidiary of Chorokbaem Media, for KRW 49 billion, renaming it Metacare and securing a healthcare distribution network.
In the first half of 2025, the company further increased its Metacare stake to strengthen control and transferred its Momolabs stake to Metacare as part of a broader portfolio realignment.
The company stated it plans to strengthen its non-reimbursed hospital CRM solution business for hair loss and diet clinics and upgrade it into an AI-based business model linked with medical data analytics.
This reflects an ongoing transition from a fashion-origin company into a composite healthcare structure spanning hospital consulting and medical distribution.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩11.8B | -₩5.1B | −43.5% |
| 2025Q3 | ₩30B | -₩200M | −0.8% |
| 2025Q4 | ₩31.1B | -₩1.1B | −3.5% |
| 2026Q1 | ₩30.4B | ₩500M | 1.7% |
| 2026Q2 | ₩27.6B | ₩300M | 1.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩22.7B | -₩2B | -₩4.1B | −9.0% | −5.2% | 14.1% |
| 2023 | ₩21.6B | -₩3.9B | -₩7.3B | −17.9% | −10.2% | 52.4% |
| 2024 | ₩38.4B | -₩3.2B | ₩200M | −8.3% | 0.3% | 67.7% |
| 2025 | ₩81.3B | -₩7.2B | -₩8.8B | −8.9% | −12.6% | 76.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue for 2025 reached KRW 81.3 billion, sharply up from KRW 38.4 billion in 2024, while the operating loss widened to KRW 7.2 billion from KRW 3.2 billion in 2024. Operating margin stayed negative for four straight years: -9.0% in 2022, -17.9% in 2023, -8.3% in 2024, and -8.9% in 2025.
Net income attributable to owners swung from a small KRW 0.2 billion profit in 2024 back to an KRW 8.8 billion loss in 2025, reflecting cost burdens tied to expanded subsidiary consolidation and new business initiatives.
On a quarterly basis, the second quarter of 2025 marked the deepest point of loss with revenue of KRW 11.8 billion and an operating loss of KRW 5.1 billion, before revenue surged to KRW 30.0 billion in the third quarter, narrowing the operating loss to KRW 0.2 billion and turning net income positive at KRW 0.2 billion.
The fourth quarter, however, saw the loss widen again to an operating loss of KRW 1.1 billion and a net loss of KRW 2.9 billion despite revenue holding around KRW 31.1 billion.
Entering 2026, the company posted two consecutive quarters of positive operating profit—KRW 0.5 billion on revenue of KRW 30.4 billion in the first quarter and KRW 0.3 billion on revenue of KRW 27.6 billion in the second quarter—yet net losses attributable to owners were larger in both quarters, at KRW 1.0 billion and KRW 2.2 billion respectively.
This divergence between operating profit and net income suggests non-operating factors such as financial costs, equity-method results, or minority interest allocation are exerting a meaningful drag on the bottom line.
Non-controlling interests within consolidated equity reached KRW 71.9 billion at the end of 2025, exceeding the KRW 69.9 billion attributable to owners, underscoring the equity structure shift stemming from expanded subsidiary consolidation.
Within the KOSPI textile, fashion, and lifestyle classification, MetaLabs' traditional casual apparel licensing business faces limited inherent growth, whereas the cosmetic and hair-loss clinic management consulting and pharmaceutical/medical device distribution markets it is expanding into are viewed as relatively faster-growing areas.
An industry source noted that Korea's medical MRO market is growing at an annual rate of about 15% and has rapidly expanded to a scale of roughly KRW 26 trillion.
However, this market features competition between numerous small distributors and large pharmaceutical or device distribution companies, meaning new entrants may take time to secure stable margins.
The hair transplant and hair-loss management segment centers on non-reimbursed procedures, exposing consulting revenue directly to fluctuations in partner hospitals' performance.
FnGuide assessed that the fashion segment is expanding sales through diverse channels and price competitiveness amid online market growth, while the management consulting segment has limited profitability due to partner hospital revenue volatility and restructuring costs.
On the healthcare distribution side, it noted the segment is building a growth foundation through recognized pharmaceutical and medical device distribution revenue and expanded hospital partnerships and non-reimbursed distribution.
Competitively, MetaLabs is pursuing a strategy of vertical linkage among affiliates such as Meta Pharm and Metacare to broaden market position, though it likely remains at a scale disadvantage relative to established large pharmaceutical and device distributors.
The company stated through its earnings release that 2026 results are expected to improve and that it plans to make 2026, built on expanded revenue, the founding year of an earnings turnaround. Achieving positive operating profit in both the first and second quarters of 2026 is consistent with this stated direction.
In June 2026, the company said it would strengthen subsidiary control and expand its mid- to long-term growth foundation through a capital structure connecting MetaLabs and Metacare as it pursued a KRW 6 billion third-party share issuance, through which MetaLabs' stake in Metacare is set to rise from 37.28% to 51.78%.
Metacare stated the raised funds would be used for future acquisitions of shares in other companies, leaving room for further acquisitions or equity investments. At the same time, concerns have been raised that this intra-group capital flow structure could deplete Metacare's own cash reserves.
In the healthcare segment, continued hospital partnership expansion and strengthened non-reimbursed distribution suggest revenue growth could persist, but whether one-off costs such as bad debt allowances recur will be key to profitability improvement.
The central points to watch going forward are whether operating profit translates into net profit in coming quarters, and whether the financial soundness of affiliates including Metacare stabilizes.
MetaLabs has tended to trade at levels below its net asset value, a pattern that can be interpreted as reflecting the repeated net losses of recent years combined with equity structure changes from subsidiary consolidation.
No dividend payment has been confirmed for the most recent fiscal year, so attention should focus on the direction of earnings flow rather than dividend-yield comparisons.
Operating profit turned positive for two consecutive quarters entering 2026, yet net income has not exited loss territory, a structural feature that should factor into how valuation multiples are interpreted, since operating improvement has not directly translated into net profit recovery.
Given the company's relatively small market capitalization, trading volume and price volatility can expand more readily, which in turn can affect price-to-book multiples.
Investors may find it more useful to track revenue growth momentum, the pace of operating margin improvement, and the timing of any net profit turnaround rather than focusing on any particular price level.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Consolidated revenue in 2025 grew 112% year over year to KRW 81.3 billion, driven mainly by newly consolidated subsidiaries such as Metacare and expanded healthcare distribution. Growth continued into 2026 with revenue of KRW 30.4 billion and KRW 27.6 billion in the first and second quarters, respectively.
Continued hospital partnership expansion and stronger non-reimbursed distribution could further broaden the revenue base.
The operating loss of KRW 5.1 billion in the second quarter of 2025 turned into operating profits of KRW 0.5 billion and KRW 0.3 billion in the first and second quarters of 2026, respectively. This suggests some improvement in cost structure alongside revenue expansion. The company has stated its intention to make 2026 the founding year of an earnings turnaround.
In June 2026, a KRW 6 billion third-party share issuance involving Meta Pharm, a party related to the controlling shareholder, was pursued, which is set to raise MetaLabs' stake in Metacare from 37.28% to 51.78%.
Direct participation by the controlling shareholder side can be read as a factual signal of capital commitment to the group structure. Strengthened control, fully incorporating Metacare as a subsidiary, could increase management's ability to steer consolidated results.
Operating profit was KRW 0.5 billion and KRW 0.3 billion in the first and second quarters of 2026, respectively, yet net losses attributable to owners in the same periods were larger, at KRW 1.0 billion and KRW 2.2 billion. This suggests non-operating items are exerting a significant drag on net income. The structural gap between operating profitability and shareholder-attributable profit has yet to close.
Following the acquisition, it was reported that Metacare's standalone cash holdings fell to KRW 14 billion at the end of the first quarter, down 53.5% from KRW 30.1 billion at the end of the prior year and down 62.2% from KRW 37 billion a year earlier.
According to the same report, borrowings surged 83.3% to KRW 50.6 billion from KRW 27.6 billion at the end of the prior year, with the debt dependency ratio rising from 17.6% to 29.1%. It was noted that funds used to support affiliates have weakened Metacare's own liquidity.
The consolidated debt ratio rose for four straight years, from 14.1% in 2022 to 52.4% in 2023, 67.7% in 2024, and 76.2% in 2025.
Operating cash flow was negative for three consecutive years—KRW -0.05 billion in 2023, KRW -3.83 billion in 2024, and KRW -2.5 billion in 2025—indicating the business has not been generating cash from operations. Despite top-line growth, the financial structure continues to rely on external funding.
There have been reports that Metacare's cash was used to participate in a MetaLabs affiliate's rights offering, consuming over 10% of its cash holdings, with board resolutions showing participation in rights offerings of KRW 2 billion and KRW 1.5 billion at Planlabs and Dyte Lab, respectively.
Repeated intra-group fund transfers of this nature could potentially conflict with minority shareholder interests at listed subsidiaries. Ongoing scrutiny of governance transparency and the purpose of fund usage is warranted.
The company explained the widened 2025 operating loss as stemming from bad debt allowance expenses. Given the nature of the healthcare distribution business, managing hospital receivables is important, and recurrence of similar bad debt charges could again disrupt the operating profit trend. Continued monitoring of receivables collection speed and credit management policy is warranted.
MetaLabs is a KOSPI-listed company with a relatively small market capitalization, and it has been observed being discussed in online investment communities in connection with certain political or health-related themes.
Such theme-driven attention can amplify trading volume and price volatility independent of underlying fundamentals. Given its small-cap characteristics, bid-ask spreads may widen during periods of lower liquidity.
Check the third-quarter 2026 report for whether the operating profit trend extends to a third quarter and whether the net loss attributable to owners narrows.
Verify completion of the KRW 6 billion share issuance payment, whether MetaLabs' Metacare stake reflects the targeted 51.78%, and the actual use of proceeds.
Examine whether subsidiary-level financial health indicators such as debt dependency, net debt, and cash holdings stabilize.
Check whether full-year revenue growth is sustained and whether the stated turnaround is actually completed with both operating profit and net profit turning positive.
MetaLabs is in the midst of transitioning from a fashion licensing business into a composite healthcare enterprise centered on hospital management consulting and pharmaceutical or medical device distribution, a shift accompanied by a clear revenue increase from KRW 38.4 billion in 2024 to KRW 81.3 billion in 2025.
Two consecutive quarters of positive operating profit in early 2026 align with the turnaround direction the company has stated, though net income attributable to owners remained in loss over the same period, confirming a drag from non-operating factors.
Direct participation by the controlling shareholder in a share issuance to expand control over subsidiary Metacare reflects group structure strengthening, but has simultaneously raised concerns about intra-group capital flows.
A debt ratio that has risen for four consecutive years and operating cash flow that has been negative for three straight years show that top-line growth has not yet translated into stable cash generation.
Going forward, the key points to watch will be whether operating profit converts into net profit and whether the financial soundness of affiliates including Metacare improves.
Investors may wish to track the durability of revenue growth, the pace of profitability recovery, and the transparency of intra-group transactions.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.